BCL11A expression in triple-negative breast cancer tissue and its response to neoadjuvant chemotherapy
Objective: To investigate the BCL11A expression in triple-negative breast cancer (TNBC) tissue, and the impact of neoadjuvant chemotherapy on its expression. Methods: The BCL11A expressions in 43 specimens of TNBC (before and after neoadjuvant chemotherapy), as well as in 49 specimens of luminal type breast cancer and 50 cases of HER-2 positive breast cancer were determined by immunochemical staining. The relations of BCL11A expression with the clinicopathologic factors of TNBC and the influence of neoadjuvant chemotherapy on BCL11A expression in TNBC were analyzed. Results: The positive expression rate and expression level of BCL11A in TNBC tissue were significantly higher than those in luminal type breast cancer tissue or HER-2 positive breast cancer tissue (all P<0.05); the positive BCL11A expression was significantly associated with the size of the primary tumor of TNBC (P<0.05); both positive expression rate and expression level of BCL11A in TNBC tissue after neoadjuvant chemotherapy were significantly reduced compared with TNBC tissue before neoadjuvant chemotherapy (both P<0.05). Conclusion: BCL11A expression is increased in TNBC tissue, which may probably be a proliferation promoting factor, and neoadjuvant chemotherapy can reduce BCL11A expression in TNBC tissue.